TP 2021
Alternative Names: JT-09; JT-09 Implant; JT-09 ProNeura implants; TP-2021Latest Information Update: 28 Dec 2024
Price :
$50 *
At a glance
- Originator JT Pharmaceuticals
- Developer JT Pharmaceuticals; Medical University of South Carolina
- Class Analgesics; Antipruritics; Peptides; Skin disorder therapies
- Mechanism of Action Opioid kappa receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Pain; Pruritus
Most Recent Events
- 28 Dec 2024 No recent reports of development identified for preclinical development in Pruritus in USA (SC, Implant)
- 28 Jun 2023 No recent reports of development identified for preclinical development in Pain in USA (PO)
- 19 Apr 2023 TP 2021 is available for licensing as of 19 Apr 2023. https://ir.titanpharm.com/